Sanofi has paid the upfront fee and committed to discovery, development and commercial milestones of over $400 million to get ...

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

Cassava Sciences is laying off 10 employees —a third of its workforce—as the biotech seeks to conserve cash in the wake of ...

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...

Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...

QPS Holdings, a contract research organization with offices in the U.S., Asia and Europe, has named Ryght AI its ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Things are heating up for FIRE1, which posted a $120 million funding round to support its implant for tracking the hidden ...